Combining forces to hit cancer stem cells: TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody show efficacy against pancreatic cancer

Combining forces to hit cancer stem cells TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody show efficacy against pancreatic cancer

TRAIL selectively kills cancer cells while bispecific antibody EpCAMxCD3 guides effector lymphocytes to cancer cells. Arming of ex vivo constructed TRAIL-lymphocytes with EpCAMxCD3 enhances contact time and affinity between lymphocytes and tumor cells and enforces tumor elimination. This boosts endo...

Full description

Saved in:
Bibliographic Details
Published in:Oncoimmunology Vol. 1; no. 5; pp. 741 - 743
Main Authors: Herr, Ingrid, Groth, Ariane, Salnikov, Alexei V., Buchler, Markus W., Moldenhauer, Gerhard
Format: Journal Article
Language:English
Published: United States Taylor & Francis 01-08-2012
Landes Bioscience
Subjects:
apoptosis
Author's View
Binding
Biology
Bioscience
bispecific antibodies
Calcium
Cancer
cancer stem cells
Cell
Cycle
gene-immunotherapy
granzyme/perforin
Landes
Organogenesis
Proteins
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:TRAIL selectively kills cancer cells while bispecific antibody EpCAMxCD3 guides effector lymphocytes to cancer cells. Arming of ex vivo constructed TRAIL-lymphocytes with EpCAMxCD3 enhances contact time and affinity between lymphocytes and tumor cells and enforces tumor elimination. This boosts endogenous immune responses and augments the effect of cytotoxic tumor therapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2162-4011
2162-402X
2162-402X
DOI:10.4161/onci.19532